This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Liquid biopsy tests used to determine eligibility for PARP inhibition among men with advanced prostate cancer are prone to false positives because of interference from clonal hematopoiesis—but analyzing plasma cell-free DNA alongside paired whole-blood control samples can correct this problem.
- ©2021 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
January 2021
Volume 11, Issue 1
Volume 11, Issue 1
Beware Liquid Biopsies to Guide PARP Blockade
Jump to section
Advertisement